...
首页> 外文期刊>The Internet Journal of Pathology >Prognostic Value Of hMLH1 And hMSH2 Immunohistochemical Expression In Non-Small Cell Lung Cancer
【24h】

Prognostic Value Of hMLH1 And hMSH2 Immunohistochemical Expression In Non-Small Cell Lung Cancer

机译:hMLH1和hMSH2免疫组织化学表达在非小细胞肺癌中的预后价值

获取原文
           

摘要

The etiologic association and prognostic significance of mismatch repair gene/protein alterations have never been examined in lung cancer. We investigated protein expression of hMLH1 and hMSH2 genes in tumor specimens from 105 non-small cell lung cancer (NSCLC) patients. 60 of them were diagnosed with adenocarcinoma, 38 with squamous cell carcinoma and seven with large cell carcinoma. Out of the 105 patients 40 (20 adenocarcinomas and 20 squamous cell carcinomas) had already received neoadjuvant chemotherapy based on carboplatine and navelbine or carboplatine vepesid. Immunohistochemical staining was used to examine protein expression. Expression in each patient was compared with clinicopathologic variables as well as overall survival and cancer-specific survival rates. Results: Alteration of protein expression was observed in 30% of patients. Loss of hMLH1 and hMSH2 protein expression was associated with significantly shorter disease-free survival in patients who had received neoadjuvant chemotherapy (p=0.05). Conclusion: Loss of immunohistochemical expression of hMLH1 and hMSH2 markers in lung tumors indicates a poorer prognosis for NSCLC patients receiving neoadjuvant therapy. Introduction Lung cancer has become the leading cause of cancer death in many industrialized countries. In Taiwan, for example, lung cancer claims more than 7,000 lives annually [13]. Much attention has recently been focused on the rapidly increasing incidence of primary lung cancer in nonsmokers [14, 21, 28]. Gender differences in distribution, histological type, and exposure to tobacco have also been noted [4, 6, 8, 16, 18]. Although 80% of female lung cancer patients worldwide have smoked at some time, less than 10% of Taiwanese women with lung cancer have any smoking history. The low smoking status and high incidence rate of adenocarcinoma constitute distinctive characteristics of lung cancer in Taiwanese females. Ryberg et al. showed that susceptibility to DNA damage caused by environmental carcinogens such as polycyclic aromatic hydrocarbon–like compounds may be higher among women than among men. They concluded that women are at greater risk of tobacco and/or environmentally induced lung cancer [19]. Takagi et al. observed a distinct mutational spectrum for the p53 gene in lung cancer tissue from nonsmoking Chinese women in Hong Kong suggesting that environmental and/or genetic factors might be involved in the development of lung cancer in these women [23]. Molecular biological studies have shown that overt cancers carry multiple genetic and epigenetic alterations, which seem to indicate the involvement of tumor suppressor genes and dominant oncogene activation during the process of carcinogenesis and subsequent progression of cancer [20, 25]. Alteration analysis of genes controlling acquired somatic mutations, such as genes involved in DNA repair, may explain the observed susceptibility to various environmental factors seen in lung cancer in nonsmoking females. hMLH1 and hMSH2 are both known to play a role in DNA mismatch repair. Their inactivation by promoter hypermethylation has been reported to be associated with some human cancers [5, 7, 12, 15, 24]. Herman et al. have suggested that DNA methylation associated with transcriptional silencing of hMLH1 is the underlying cause of mismatch repair defects in most sporadic colorectal cancers [12]. Xinarianos et al. have shown that 58.6% and 57.8% of lung cancer tumor specimens had reduced expression levels of the hMLH1 and hMSH2 proteins, respectively [29]. The clinical significance of protein expression of hMLH1 and hMSH2 in lung cancers remains unclear. Recently, Brooks et al. reported that low protein expression of hMSH2 in positive mediastinal nodal specimens was associated with poor treatment response and cancer death in patients with stage III non–small cell lung cancer (NSCLC) [2]. In a previous study protein expression and status of promoter hypermethylation of hMLH1 and hMSH2 in 77 NSCLC
机译:从未在肺癌中检查错配修复基因/蛋白质改变的病因学关联和预后意义。我们调查了105名非小细胞肺癌(NSCLC)患者的肿瘤标本中hMLH1和hMSH2基因的蛋白表达。其中60例被诊断为腺癌,38例为鳞状细胞癌,7例为大细胞癌。在105例患者中,有40例(20例腺癌和20例鳞状细胞癌)已经接受了基于卡铂和纳维滨或卡铂维比西德的新辅助化疗。免疫组织化学染色用于检查蛋白质表达。将每个患者的表达与临床病理变量以及总生存期和癌症特异性生存率进行比较。结果:在30%的患者中观察到蛋白质表达的改变。在接受新辅助化疗的患者中,hMLH1和hMSH2蛋白表达的丧失与无病生存期明显缩短有关(p = 0.05)。结论:肺肿瘤中hMLH1和hMSH2标记物的免疫组化表达丧失表明接受新辅助治疗的NSCLC患者预后较差。简介肺癌已经成为许多工业化国家癌症死亡的主要原因。例如,在台湾,肺癌每年夺走7,000多条生命[13]。最近,很多注意力都集中在非吸烟者中原发性肺癌的发病率迅速上升[14,21,28]。还注意到性别分布,组织学类型和接触烟草的差异[4、6、8、16、18]。尽管全世界有80%的女性肺癌患者曾经吸烟,但只有不到10%的台湾女性肺癌患者有吸烟史。吸烟率低和腺癌的高发病率构成台湾女性肺癌的显着特征。 Ryberg等。研究表明,环境致癌物(如多环芳烃样化合物)引起的DNA损伤的敏感性可能比男性高。他们得出的结论是,妇女罹患烟草和/或环境诱发的肺癌的风险更大[19]。高木等。观察到来自香港非吸烟中国女性肺癌组织中p53基因的独特突变谱,表明环境和/或遗传因素可能与这些女性肺癌的发展有关[23]。分子生物学研究表明,公开的癌症具有多种遗传和表观遗传学改变,这似乎表明在癌变过程和随后的癌症发展过程中,抑癌基因的参与和显性癌基因的激活[20,25]。控制获得性体细胞突变的基因的变异分析,例如涉及DNA修复的基因,可以解释观察到的非吸烟女性对各种环境因素的敏感性。众所周知,hMLH1和hMSH2都在DNA错配修复中起作用。据报道,它们通过启动子高甲基化而失活与某些人类癌症有关[5、7、12、15、24]。赫尔曼等。有人认为,与hMLH1转录沉默相关的DNA甲基化是大多数散发性结直肠癌中错配修复缺陷的根本原因[12]。 Xinarianos等。已有58.6%和57.8%的肺癌肿瘤标本分别降低了hMLH1和hMSH2蛋白的表达水平[29]。尚不清楚hMLH1和hMSH2蛋白在肺癌中的临床意义。最近,布鲁克斯等。有报道称,III期非小细胞肺癌(NSCLC)患者中,纵隔淋巴结阳性标本中hMSH2的低蛋白表达与不良的治疗反应和癌症死亡相关[2]。在先前的研究中,在77个NSCLC中,hMLH1和hMSH2的蛋白表达和启动子高甲基化状态

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号